Lazard Asset Management
AIMT

Lazard Asset Management’s Aimmune Therapeutics AIMT Stock Holding History

Lazard Asset Management’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-202
Closed -$3K – 1806
2020
Q2 		$3K Buy
+202
New +$3.43K ﹤0.01% 1551
2018
Q2 		– Sell
-12,222
Closed -$389K – 1149
2018
Q1 		$389K Buy
+12,222
New +$430K ﹤0.01% 793

Other funds holding AIMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lazard Asset Management's AIMT Position: Q3 2020 in Review

Lazard Asset Management sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 202 shares — an estimated $3K sold.

Lazard Asset Management first reported a position in AIMT in Q1 2018 and held it in 2 quarters. The position peaked at $389K in Q1 2018. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

  • Lazard Asset Management reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Lazard Asset Management sold 202 Aimmune Therapeutics shares in Q3 2020, an estimated $3K.
  • Lazard Asset Management first reported a position in Aimmune Therapeutics in Q1 2018 and held it in 2 quarters.
  • Lazard Asset Management's Aimmune Therapeutics position peaked at $389K in Q1 2018.
  • 188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Lazard Asset Management's 13F filing for Q3 2020, filed 13 Nov 2020.